CHD7 is the most amplified CHD protein, represented in around 11% breast cancer patients (Figure 4) and its amplifications are more prevalent in aggressive breast cancer subtypes, correlating with high tumor grade and poor prognosis. Here, CHD7 is linked to breast carcinoma.